ESC 365 - Maximally tolerated guideline-directed medical therapy and barriers to optimization in patients with heart failure with reduced ejection fraction: The COAPT trial

ESC Professional Premium Access

Maximally tolerated guideline-directed medical therapy and barriers to optimization in patients with heart failure with reduced ejection fraction: The COAPT trial

Session: Heart failure pharmacology

Topic: Pharmacotherapy

Speaker: Professor Z. Cox (Nashville, US)

Event: ESC Congress 2022

Congress Presentation

Add to my library

About the speaker

Professor Zachary Cox

Lipscomb University College of Pharmacy, Nashville (United States of America)

3 presentations

1 follower

6 more presentations in this session

Adherence and discontinuation of optimal heart failure therapies according to age

Speaker: Miss C. Garred (Gentofte, DK)

Real-world eligibility for vericiguat according to trial, guideline, and labelling eligibility criteria: data from the Swedish Heart Failure Registry

Speaker: Mr V. Nguyen (Stockholm, SE)

Efficacy of sodium glucose cotransporter 2 inhibitors for heart failure with preserved and mildly reduced ejection fraction: a systematic review and meta-analysis

Speaker: Doctor K. Rivera (Manila, PH)

Compliance to guideline-recommended pharmacotherapy in patients with heart failure, 2014 to 2020

Speaker: Doctor K. Odegaard (Oslo, NO)

Comparative efficacy of novel drugs as an addition to guideline-directed medical therapy for heart failure with reduced ejection fraction: a network meta-analysis of randomised controlled trials

Speaker: Mr T. Suebsaicharoen (Bangkok, TH)

Access the full session

Heart failure pharmacology

Speakers: Professor Z. Cox, Miss C. Garred, Mr V. Nguyen, Doctor K. Rivera, Doctor K. Odegaard...

About the event

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources